mecamylamine has been researched along with Schwartzman Phenomenon in 1 studies
Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using the Shwartzman reaction, we observed that nicotine (2 mg/kg) and the novel cholinergic agent CAP55 (12 mg/kg) inhibit endothelial cell adhesion molecule expression." | 1.33 | Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. ( Al-Abed, Y; Balakhaneh, D; Huston, J; Metz, CN; Peng-Nemeroff, T; Saeed, RW; Sherry, B; Tracey, KJ; Varma, S, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saeed, RW | 1 |
| Varma, S | 1 |
| Peng-Nemeroff, T | 1 |
| Sherry, B | 1 |
| Balakhaneh, D | 1 |
| Huston, J | 1 |
| Tracey, KJ | 1 |
| Al-Abed, Y | 1 |
| Metz, CN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Inflammatory and Biomechanical Contributors to Arthritis Development Following Arthroscopic Meniscectomy[NCT00752271] | 32 participants (Anticipated) | Observational | 2008-05-31 | Terminated | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for mecamylamine and Schwartzman Phenomenon
| Article | Year |
|---|---|
Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation.
Topics: Acetylcholine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Blotting, Western; Carrageenan; Cel | 2005 |